[
    [
        {
            "time": "2018-12-10",
            "original_text": "每周医药生物行业机构观点选编（2018年12月10日~12月16日）",
            "features": {
                "keywords": [
                    "医药生物",
                    "机构观点",
                    "周报"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "每周医药生物行业机构观点选编（2018年12月10日~12月16日）",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-12-10",
            "original_text": "医药生物行业周报: 政策多发扰动期, 建议关注品牌中药的配置价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策",
                    "品牌中药",
                    "配置价值"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物",
                    "中药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报: 政策多发扰动期, 建议关注品牌中药的配置价值",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "医药行业2019年年度投资策略报告: 继续看好创新药企及细分领域龙头企业的發展",
            "features": {
                "keywords": [
                    "医药行业",
                    "创新药",
                    "龙头企业",
                    "投资策略"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "创新药",
                    "龙头企业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2019年年度投资策略报告: 继续看好创新药企及细分领域龙头企业的發展",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        }
    ]
]